Categorical and dimensional approaches to negative symptoms of schizophrenia: Focus on long-term stability and functional outcome
Introduction
Negative symptoms of schizophrenia represent a heterogeneous psychopathological domain. In fact, they include signs and symptoms favourably responding to currently available treatments (for instance, negative symptoms secondary to positive or depressive symptomatology, that might respond well to available antipsychotics or adjunctive antidepressants), but also signs and symptoms still representing a challenge for the development of new pharmacological and non-pharmacological interventions (for instance, primary and persistent negative symptoms, Kirkpatrick and Galderisi, 2008, Galderisi and Maj, 2009). Research focussing on deconstruction of broadly defined negative symptoms might be crucial to identify key targets for new treatments aimed to improve patients' outcome.
A categorical approach within this research field has been represented by the study of deficit schizophrenia (DS). It is regarded as a distinct subtype within the diagnosis of schizophrenia, characterized by the presence of primary and enduring negative symptoms, and showing different clinical, neuropsychological and neurobiological abnormalities with respect to nondeficit schizophrenia (NDS; Carpenter et al., 1988, Kirkpatrick et al., 1998, Kirkpatrick et al., 2000, Kirkpatrick and Galderisi, 2008, Galderisi and Maj, 2009). Three studies, so far, investigated the stability of the diagnosis across time and the long-term outcome of patients bearing the diagnosis of DS: one was based on a retrospective assessment (Fenton and McGlashan, 1994) and two of them on a prospective design (Amador et al., 1999, Strauss et al., 2010). The frequency of confirmed diagnoses at follow-up ranged from 67% to 83.3%. The lowest figure was reported by Strauss et al. (2010), in a 20-year follow-up study (the longest follow-up interval in the relevant literature), involving 39 patients with schizophrenia categorized as DS (N = 14) or NDS (N = 25) using a proxy method; the highest frequency was reported by Amador et al. (1999) in a study involving 43 patients with schizophrenia or schizoaffective disorder, in which the DS/NDS categorization was performed by means of the Schedule for the Deficit Syndrome (SDS). Few prospective studies investigated long-term functional outcome of subjects with DS or NDS. Two of them reported a poorer outcome in DS than in NDS patients (Tek et al., 2001, Strauss et al., 2010), while Chemerinski et al. (2006), in a group of elderly patients with DS or NDS (the latter ones were subdivided into delusional and disorganized type) reported greatest functional impairment in delusional, lowest in disorganized and intermediate in the DS group, at odds with the other studies showing poorer functioning in patients with DS than in those with NDS.
More recently a dimensional approach to the study of negative symptoms has been revived by investigations based on factor analyses of negative symptoms showing that two separate factors, i.e. Avolition and Poor Emotional Expression, can be identified both when the overall negative domain is assessed (Blanchard and Cohen, 2006, Kirkpatrick et al., 2011, Strauss et al., 2012) and when only primary and enduring negative symptoms are evaluated (Kimhy et al., 2006, Nakaya and Ohmori, 2008). No study, so far, examined the SDS factor structure stability across time and the ability of SDS factors to predict functional outcome.
In the present investigation both a categorical and a dimensional approach were used to assess long term-stability and outcome of negative symptoms. In particular, within the former approach, we investigated the long-term stability of the DS and NDS diagnosis and the long-term outcome of patients with DS or NDS. In the frame of a dimensional approach, we assessed the factor structure and stability of broadly defined negative symptoms and the impact of the identified factors on functional outcome.
Premorbid adjustment, general cognitive abilities and other neuropsychological domains, psychopathological dimensions and neurological signs were investigated in the two groups as these variables can influence functional outcome in patients with schizophrenia (Breier et al., 1991, Dickerson et al., 1996, Dickerson et al., 1999, Green et al., 2000, Galderisi and Maj, 2009, Hunter and Barry, 2012, Peralta et al., 2012).
Section snippets
Study design
In the baseline study historical, clinical, neuropsychological and neuroradiological aspects had been assessed in 58 subjects with DS and 54 with NDS, recruited in 4 Italian University Departments of Psychiatry (Galderisi et al., 2002, Galderisi et al., 2008). After 5 years, all patients included in the baseline study and still attending the above mentioned Departments were contacted by their physician. Patients willing to participate in the follow-up study were re-administered the SDS by
Subjects
Fifty-one out of 58 patients diagnosed as DS in the baseline study and 44 out of 54 patients diagnosed as NDS were recruited at follow-up. The remaining patients were not included for the following reasons: 2 of them had died (one for suicide and another for unspecified natural causes), 8 had moved to a different region from the one where they were first recruited, 7 refused to participate in the study. The deficit/nondeficit categorization was available in the whole study sample, while the
Discussion
In the present study a deconstruction of the negative symptoms heterogeneous construct was attempted by using both a categorical and a dimensional approach. The main focus was on longitudinal stability and impact on functional outcome of different aspects of negative symptoms.
The categorical approach showed a high longitudinal stability for both DS and NDS diagnoses: after a 5-year follow-up, the DS/NDS categorization was confirmed in 82.4% of patients previously diagnosed as DS and in 79.6% of
Role of funding source
The present multicenter study was supported by grant 2003064871 from the Italian Ministry of University and Scientific Research.
Contributors
MM, SG, AV, AR and SP contributed to the conception and design of the study. SG, AM and PB analyzed and interpreted the data and drafted the manuscript. All Authors participated in the critical revision of the manuscript and provided the final approval of the version to be published.
Conflicts of interest
SG, in the last five years, received fees for educational programs or advisory boards from Amgen Dompé, AstraZeneca, Bristol-Myers Squibb, Eli-Lilly, Otsuka, Innova-Pharma and Janssen-Cilag.
PB and SP have declared no conflict of interest.
AM, in the last five years, received fees for educational programs by AstraZeneca, Innova-Pharma, Bristol-Myers Squibb and Janssen-Cilag.
BK, in the last two years, had financial relationships with Abbott Laboratories, Genentech, Roche, and Bristol-Myers Squibb.
Acknowledgements
The authors would like to thank all subjects who participated in the study.
References (34)
- et al.
Three dimensions of clinical symptoms in elderly patients with schizophrenia: prediction of six-year cognitive and functional status
Schizophr. Res.
(2006) - et al.
Neurocognitive deficits and social functioning in outpatients with schizophrenia
Schizophr. Res.
(1996) - et al.
Flat affect and social functioning: a 10 year follow-up study of first episode psychosis patients
Schizophr. Res.
(2012) - et al.
Prediction of longitudinal functional outcomes in schizophrenia: the impact of baseline motivational deficits
Schizophr. Res.
(2011) - et al.
Deficit schizophrenia: an overview of clinical, biological and treatment aspects
Eur. Psychiatry
(2009) - et al.
Negative symptoms and psychosocial functioning in schizophrenia: neglected but important targets for treatment
Eur. Psychiatry
(2012) - et al.
Apathy in schizophrenia: clinical correlates and association with functional outcome
Schizophr. Res.
(2003) - et al.
A two-factor structure for the Schedule for the Deficit Syndrome in schizophrenia
Psychiatry Res.
(2008) - et al.
Factor structure of the brief negative symptom scale
Schizophr. Res.
(2012) - et al.
A five-year follow-up study of deficit and nondeficit schizophrenia
Schizophr. Res.
(2001)
Awareness of illness in schizophrenia and schizoaffective and mood disorders
Arch. Gen. Psychiatry
Stability of the diagnosis of deficit syndrome in schizophrenia
Am. J. Psychiatry
The structure of negative symptoms within schizophrenia: implications for assessment
Schizophr. Bull.
Toward the next generation of negative symptom assessments: the collaboration to advance negative symptom assessment in schizophrenia
Schizophr. Bull.
National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome
Arch. Gen. Psychiatry
Deficit and nondeficit forms of schizophrenia: the concept
Am. J. Psychiatry
Predictors of residential independence among outpatients with schizophrenia
Psychiatr. Serv.
Cited by (138)
Time is the enemy: Negative symptoms are related to even slight differences in the duration of untreated psychosis
2024, Comprehensive PsychiatryThe longitudinal structure of negative symptoms in treatment resistant schizophrenia
2024, Comprehensive PsychiatryNegative symptoms in drug-naive patients with a first-episode psychosis (FEP)
2023, Asian Journal of PsychiatryNegative symptoms of schizophrenia: Trying to answer unanswered research questions
2023, Psychiatry Research